• Kastner J, Hossain R. White CS. Epidemiology of Lung Cancer SEMIN ROENTGENOL. 2019;1(55):36–53.


    Google Scholar
     

  • Yang D, Liu Y, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer lett. 2020;468(5):82–7.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. Ca Cancer J Clin. 2017;67(1):7–30.

    Article 
    PubMed 

    Google Scholar
     

  • Anish T, Yuanbin C, Tinghui Y, Marko J, Giuseppe G. Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. Front Oncol. 2015;5(33):113–9.


    Google Scholar
     

  • Wilkes GM. Targeted Therapy Attacking Cancer with Molecular and Immunological Targeted Agents. Asia Pac J Oncol Nurs. 2018;5(2):137–55.

    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. JAMA. 2019;321(14):1391–402.

    CAS 
    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Ettinger DS, Wood DE, Akerley W, Dhila. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016;14(3):255–64.

    Article 
    PubMed 

    Google Scholar
     

  • Wang MC, Wang CL, Chen TL, Chang WC, Lu JJ, Chang PY, et al. Predicting outcomes of EGFR-targeted therapy in non-small cell lung cancer patients using pleural effusions samples and peptide nucleic acid probe assay. Clin Chem Lab Med. 2017;55(12):1979–86.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Kale HP, Mays D’AP, Nadpara PA, Slattum PW. Economic Burden Of Renal Cell Carcinoma Among Older Adults In The Targeted Therapy ERA. Urol Oncol. 2019;37:e19-28.

    Article 

    Google Scholar
     

  • Varvaresou A, Iakovou K, Mellou F, Myrogiannis D, Papageorgiou S. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management. J Cosmet Dermatol-US. 2020;20(3):1–7.


    Google Scholar
     

  • Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015;33(32):3817–25.

    CAS 
    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Tischer B, Huber R, Kraemer M, Lacouture ME. Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer. 2017;25(2):651–60.

    Article 
    PubMed 

    Google Scholar
     

  • Lee JL, Jeong Y. Quality of Life in Patients With Non-Small Cell Lung Cancer: Structural Equation Modeling. Cancer Nurs. 2018;42(6):475–83.

  • Barrios DM, Phillips GS, Freites-Martinez A, Hsu M, Lacouture ME. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol. 2019;34(6):27–39.


    Google Scholar
     

  • Yagasaki K, Komatsu H, Soejima K, Naoki K, Hamamoto Y. Targeted Therapy-induced Facial Skin Toxicities: Impact on Quality of Life in Cancer Patients. Asia Pac J Oncol Nurs. 2018;5(2):172–7.

    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Chan JC, Lee YH, Liu CY, Shih HH, Tang WR. A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. J NURS RES. 2019;27(6):51–9.

    Article 

    Google Scholar
     

  • Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279–87.

    CAS 
    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Pouliot A, Vaillancourt R, Stacey D, Suter P. Defining and identifying concepts of medication literacy An international. Res Soc Admin Pharm. 2017;15(6):632–40.


    Google Scholar
     

  • Cordina M, Meen-Anttila K, Lauri J, Tabone S, Enlund H. Health and medication literacy and the desire to participate in pharmacotherapy decision making – comparison of two countries. Res Social Adm Pharm. 2018;14(9):817–23.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Chun-Hsien L, Chang FC, Sheng-Der H, Chi HY, Huang LJ, Ming-Kung Y, et al. Inappropriate self-medication among adolescents and its association with lower medication literacy and substance use. PLoS ONE. 2017;12(12): e189199.


    Google Scholar
     

  • Miao NF, Wang TC, Chang FC, Lee CH, Chi HY, Huang LJ, et al. Prevalence and association of pain experiences, medication literacy, and use of medication among children and adolescents in Taiwan. J Pediatr Nurs. 2019;33(8):376–83.


    Google Scholar
     

  • Persell SD, Karmali KN, Lazar D, Friesema EM. Effect of Electronic Health Record-Based Medication Support and Nurse-Led Medication Therapy Management on Hypertension and Medication Self-management A Randomized Clinical Trial. JAMA Intern Med. 2018;26(9):11–9.


    Google Scholar
     

  • Yu SP, Mehta G, Kuo MG, et al. The Effect of Health Literacy on Medication Knowledge and Medication Discrepancy in Chinese Americans. J Pharm Technol. 2015;31(6):356–65.


    Google Scholar
     

  • Tseng LC, Chen KH, Wang CL, Weng LC. Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. Med. 2020;99(23):205–10.


    Google Scholar
     

  • Sauceda JA, Loya AM, Sias JJ, Taylor T, Wiebe JS, Rivera JO. Medication literacy in Spanish and English: psychometric evaluation of a new assessment tool. J Americ Pharma Associa. 2012;52(6):e231–40.

    Article 

    Google Scholar
     

  • Zheng F, Zhong ZQ, Ding SQ, Luo AJ. Modification and evaluation of assessment of medication literacy. J Cent South Univ. 2016;41(11):1226–31.


    Google Scholar
     

  • Barton-Burke M, Ciccolini K, Mekas M, Burke S. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care. Nurs Clin N Am. 2017;1(52):83–113.

    Article 

    Google Scholar
     

  • Yamamoto K, Yano I. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. Med Oncol. 2018;35(2):16–26.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Deutsch A, Leboeuf NR, Lacouture ME, Mclellan BN. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy. Proc Am Soc Clin Oncol. 2020;40(40):485–500.


    Google Scholar
     

  • Chen CB, Wu MY, Yee NC, Lu CW, Wu J, Pei-Han K, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Manag Res. 2018;10:1259–73.

    CAS 
    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Paul T, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kachele V, et al. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients. Eur J Cancer. 2014;50(11):1855–63.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Cazzaniga ME, Danesi R, Girmenia C, Invernizzi P, Elvevi A, Uguccioni M. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success. Breast Cancer Res Treat. 2019;176(3):483–94 ([Journal Article; Review]).

    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • CLELL HASENBANK. Supportive Care and Management of Treatment-Emergent Adverse Events With Targeted Therapy in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology. 2017;35(5):1277–85.


    Google Scholar
     

  • Occhipinti M, Brambilla M, Galli G, Manglaviti S, Prelaj A, Ferrara R, et al. Drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment. J Thorac Oncol. 2021;16(4):1257–65.

    Article 

    Google Scholar
     

  • Kafatos G, Dube S, Burdon P, Demonty G, Flinois A, Leclerc M, et al. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers – ScienceDirect. Clin Colorectal Canc. 2020;19(2):100–8.

    Article 

    Google Scholar
     

  • Chan J, Lee Y, Liu C, Shih H. A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. J Nurs Res. 2019;27(6):51–9.

    Article 

    Google Scholar
     

  • Sano K, Nakadate K, Hanada K. Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer. BMC Cancer. 2020;20(1):279–87.

    CAS 
    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Braden RL, Anadkat MJ. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections. Support Care Cancer. 2016;24(9):3943–50.

    Article 
    PubMed 

    Google Scholar
     

  • FISCHER-CARTLIDGE EA. Assessment and Management of Gastrointestinal Toxicities and Lab Abnormalities Related to Targeted Therapy. Seminars Oncol Nurs. 2014;30(3):183–9.

    Article 

    Google Scholar
     

  • Orrevall Y, Tishelman C, Permert J, Cederholm T. Nutritional support and risk status among cancer patients in palliative home care services. SUPPORT CARE CANCER. 2009;17(2):153–61.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Zhong Z, Ma G, Zheng F, Duan Y, Luo A. Medication Literacy in a Cohort of Chinese Patients Discharged With Essential Hypertension. Front Public Health. 2020;7(9):385.

    PubMed Central 
    Article 
    PubMed 

    Google Scholar
     

  • Silva D, Gomes A, Lobo JM, Almeida V, Almeida IF. Management of skin adverse reactions in oncology. J Oncol Pharm Pract. 2020;26(7):1703–14.

    Article 
    PubMed 

    Google Scholar
     

  • Sefah IA, Kordorwu HE, Essah DO, Kurdi A, Godman B. Prevalence and Determinants of Serious Spontaneously Reported Adverse Drug Events Among Three Outpatient Care Settings in Ghana: Findings and Implications. Value in Health Regional Issues. 2020;22(6):38–47.

    Article 

    Google Scholar
     

  • Zhong Z, Zheng F, Guo Y, Luo A. Medication Literacy in a Cohort of Chinese Patients Discharged with Acute Coronary Syndrome. Inter J Envir Res. 2016;13(7):720–6.


    Google Scholar
     

  • Zheng F, Ding S, Luo A, Zhong Z, Duan Y, Shen Z. Medication literacy status of outpatients in ambulatory care settings in Changsha. China J Inter Med Res. 2017;45(1):303–9.


    Google Scholar
     

  • Kamal AK, Khalid W, Zulfiqar M, Muqeet A, Zaidi F, Gowani A, et al. The potential of m-Health-based interventions to improve medication literacy and adherence in non-communicable diseases in Pakistan. Int J Stroke. 2019;66(5):1235–43.


    Google Scholar
     

  • Cordinaa M, Hämeen-Anttilac K, Laurib J, Tabone S. Health and medication literacy and the desire to participate in pharmacotherapy decision making – comparison of two countries. Res Soc Admin Pharm. 2018;14(9):817–23.

    Article 

    Google Scholar
     

  • Krajnovi, Du Anka, Ubavi, Stana, Bogavac-Stanojevi, A N. Pharmacotherapy Literacy and Parental Practice in Use of Over-the-Counter Pediatric Medicines. Medicina. 2019;51(22):985–92.

  • Staats H, Cassidy C, Kelso J, Mack S, Nemunaitis J. Targeted Molecular Therapy in Palliative Cancer Management. Biomed. 2020;5(13):27–49.


    Google Scholar
     

  • Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label ENSURE study. Ann Oncol. 2015;26(9):1883–9.

    Article 
    PubMed 

    Google Scholar
     

  • Sequist LV, James Chih-Hsin Y, Nobuyuki Y, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–34.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Shi YK, Wang L, Han BH, et al. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomizedstudy. Ann Oncol. 2017;28(10):2443–50.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Macdonald JB, Macdonald B, Golitz LE, Lorussoand P, Sekulic A. Cutaneous adverse effects of targeted therapies Part II: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):221–38.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Macdonald JB, Macdonald B, Golitz LE, et al. Cutaneous adverse effects of targeted therapies Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72(2):203–20.

    CAS 
    Article 
    PubMed 

    Google Scholar
     

  • Kim YS, Ji JH, Oh SY, Leeand S, Kang JH. A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor induced Skin Toxicities. Oncologist. 2019;25(1):2019–31.


    Google Scholar
     

  • Honda Y, Hattori Y, Katsura S, et al. Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib. Eur J Dermatol. 2016;26(4):413–4.

    Article 
    PubMed 

    Google Scholar
     

  • Chen CB, Wu MY, Yee NC, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies. Cancer Management & Research. 2018;10:1259–73.

    CAS 
    Article 

    Google Scholar
     

  • Rights and permissions

    Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

    Disclaimer:

    This article is autogenerated using RSS feeds and has not been created or edited by OA JF.

    Click here for Source link (https://www.biomedcentral.com/)